Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesAlvotech

Alvotech

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
4.92 USD 0.04 ( 0.82%)
Last update at 2026-11-11T21:03:00Z
VOLUME
777655
Market Cap
1095.29M
P/E
35.10

Momentum Score

…

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.87
Low
5.03
High
52 Week Price Range
3.03
Low
11.85
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Alvotech is a biopharmaceutical company developing and manufacturing biosimilar monoclonal antibody therapeutics with an integrated R&D and production platform. Its long-term growth is driven by an advancing pipeline of late-stage biosimilars, in-house manufacturing capacity and the expanding global demand for lower-cost biologics, which may benefit investors seeking exposure to the biosimilars sector.

The chief investment risks are regulatory approval uncertainty and patent-litigation around reference biologics, combined with intense pricing and commercialization competition that could constrain uptake and margins.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.88
Dividend Yield
-
Revenue TTM
588.90M
Revenue Per Share
2.03
Gross Profit TTM
353.35M
Debt / Equity
-5.09
ROE
-
Net Debt
1276.79M
ROCE
24.14%
Diluted EPS TTM
0.10

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 136.35M -217.56M -651.05M -551.65M -149.20M
Net income 27.92M -231.86M -551.73M -513.58M -101.50M
Selling general administrative 90.95M 61.45M 73.04M 186.74M 84.13M
Gross profit 350.76M 304.37M -69.42M 18.93M 36.77M
Reconciled depreciation 37.85M 31.30M 24.21M 20.41M 18.20M
Ebit 285.54M -63.58M -517.88M -346.44M -235.46M
Ebitda 323.39M -32.27M -493.67M -326.07M -168.11M
Depreciation and amortization 37.85M 31.30M 24.21M 20.37M 67.35M
Operating income 78.21M 69.64M -354.86M -346.44M -235.46M
Other operating expenses 508.11M 420.04M 446.29M 429.47M 272.23M
Interest expense 149.19M 157.60M 134.82M 188.42M 117.36M
Tax provision 108.43M 14.30M -99.32M -38.07M -47.69M
Interest income 198.49M 4.62M 4.82M 0.91M 0.02M
Net interest income 49.30M -152.98M -130.00M -90.53M -114.54M
Income tax expense 108.43M 14.30M -99.32M -38.07M -47.69M
Total revenue 586.32M 489.68M 91.43M 83.03M 36.77M
Total operating expenses 272.56M 234.73M 285.44M 365.38M 272.23M
Cost of revenue 235.56M 185.31M 160.86M 64.09M -
Total other income expense net 58.14M -287.21M -296.19M -205.21M 86.26M
Net income from continuing ops 27.92M -231.86M -551.73M -513.58M -101.50M
Net income applicable to common shares - - - -513.58M -101.50M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1487.10M 1221.40M 950.09M 828.44M 597.98M
Intangible assets 81.83M 20.62M 19.08M 25.65M 21.51M
Other current assets 111.86M 23.98M 22.04M 32.95M 9.32M
Total liab 1771.59M 1634.17M 1882.58M 1392.86M 733.59M
Total stockholder equity -284.49M -412.77M -932.49M -564.42M -135.61M
Other current liab 126.87M 67.87M 73.50M 56.11M 43.49M
Common stock 2.93M 2.83M 2.28M 2.13M 0.14M
Capital stock 2.93M 2.83M 2.28M 2.13M 0.14M
Retained earnings -2409.79M -2437.71M -2205.84M -1654.11M -1140.53M
Other liab - - - 445.54M 108.77M
Good will 12.84M 11.33M 12.06M 11.64M 12.37M
Other assets - - - 243.75M 183.65M
Cash 172.36M 51.43M 11.16M 66.43M 17.56M
Total current liabilities 304.08M 193.40M 260.95M 167.29M 111.84M
Current deferred revenue - 15.98M 59.18M 36.91M 29.69M
Net debt 1276.79M 1138.81M 1064.32M 738.67M 505.50M
Short term debt 49.00M 42.22M 47.71M 25.08M 10.07M
Short long term debt 36.92M 32.70M 38.02M 19.92M 2.77M
Short long term debt total 1449.14M 1190.24M 1075.47M 805.10M 523.05M
Other stockholder equity 2105.69M 2007.06M 1229.69M 1058.43M 1000.12M
Property plant equipment - - - 268.10M 205.33M
Total current assets 574.01M 455.02M 194.84M 230.74M 119.82M
Long term investments - 0.00M 18.49M 48.57M 55.31M
Net tangible assets - - - -601.71M -169.49M
Net receivables 69.74M 251.72M 87.22M 59.89M 53.88M
Long term debt 1262.15M 1035.88M 922.13M 744.65M 398.14M
Inventory 220.05M 127.89M 74.43M 71.47M 39.06M
Accounts payable 126.12M 67.13M 80.56M 49.19M 28.59M
Accumulated other comprehensive income 16.68M 15.05M 41.38M 29.14M 4.67M
Non currrent assets other 269.81M 3.62M 39.23M 34.25M 13.23M
Non current assets total 913.08M 766.38M 755.25M 597.71M 478.16M
Capital lease obligations 150.08M 121.65M 115.31M 40.53M 122.14M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -18.87M -46.34M -63.54M -40.63M
Change to liabilities - - - 35.84M 35.79M
Total cashflows from investing activities -104.22M -18.87M -46.34M -63.54M -40.63M
Net borrowings 197.69M 151.98M 171.19M 257.82M 68.97M
Total cash from financing activities 270.83M 297.31M 301.32M 424.91M 254.83M
Change to operating activities - - - -38.52M 0.34M
Net income 27.92M -231.86M -551.73M -513.58M -101.50M
Change in cash 120.93M 40.27M -55.27M 48.87M -14.13M
Begin period cash flow 51.43M 11.16M 66.43M 17.56M 31.69M
End period cash flow 172.36M 51.43M 11.16M 66.43M 17.56M
Total cash from operating activities -50.20M -236.84M -312.19M -312.39M -228.17M
Issuance of capital stock 82.48M 150.45M 136.88M 0.00M 185.86M
Depreciation 37.85M 31.30M 24.21M 20.41M 18.20M
Other cashflows from investing activities - 22.79M -13.11M -14.91M -14.91M
Change to inventory -90.13M -49.97M -11.30M -32.41M -29.41M
Change to account receivables -6.33M -164.24M -24.83M -3.58M -28.81M
Other cashflows from financing activities -10.37M -5.13M -6.75M 520.77M 113.82M
Change to netincome - - - 145.24M -139.64M
Capital expenditures 64.47M 57.00M 46.47M 49.00M 40.63M
Change in working capital -117.64M -288.64M 26.33M -47.89M -6.81M
Stock based compensation 17.38M 7.63M 18.03M 10.32M -22.32M
Other non cash items -124.14M 230.44M 270.29M 256.42M -68.04M
Free cash flow -114.67M -293.84M -358.66M -361.39M -268.80M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ALVO
Alvotech		 0.04
0.82%		 4.92 35.10 7.91 1.86 - 4.11 7.74
MKKGY
Merck KGaA ADR		 0.13
0.39%		 33.80 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 169.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -
-%		 20.84 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16 2.94 23.11

Profile*

Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

9, Rue de Bitbourg, Luxembourg, Luxembourg, 1273

354 422 4500

https://www.alvotech.com

1279

Name Title Year Born
Mr. Robert Wessman Founder & Exec. Chairman of Directors 1970
Mr. Mark Levick Chief Exec. Officer 1964
Mr. Joel Morales Chief Financial Officer 1978
Mr. Sean Gaskell Chief Technical Officer 1982
Mr. Joseph E. McClellan Chief Scientific Officer 1974
Ms. Rose-Marie Ohlsson Chief Information Officer NA
Ms. Sigridur Elin Gudlaugsdottir VP of HR NA
Ms. Tanya Zharov Deputy Chief Exec. Officer 1967
Mr. Anil Okay Chief Commercial Officer 1986
Mr. Ming Li Chief Strategy Officer 1977

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…